Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19.

Qu, Jian; Li, Guo-Hua; Wang, Jiao-Jiao; He, Ge-Fei; Huang, Juan-Juan; Chen, Ying; Qu, Qiang; Chen, Xiang-Yu; Lu, Qiong

The Coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. Here we evaluated the efficacy of the Lopinavir/Ritonavir (LPV/r) and its combination with other drugs in the treatment of COVID-19. We included 170 confirmed COVID-19 patients who had been cured and discharged. Their antiviral therapies were LPV/r alone or combinations with Interferon (IFN), Novaferon and Arbidol. We evaluated the medications efficacy by comparing the time of the negative nucleic acid conversion and the length of hospitalization mainly. The LPV/r+Novaferon [6.00(4.00-8.00) &7.50(5.00-10.00) days] had shorter time of the negative nucleic acid conversion (P=0.0036) and shorter time of hospitalization(P<0.001) compared with LPV/r alone [9.00(5.00-12.00) &12.00(11.00-15.00) days] and LPV/r+ IFN [9.00(7.25-11.00) &12.00(10.00-13.50) days]. On the contrary, LPV/r+IFN [9.00(7.25-11.00) & 12.00(10.00-13.50) days] had shorter time of the negative nucleic acid conversion (P=0.031) and shorter time of hospitalization (P<0.001) compared with LPV/r+IFN+Novaferon [10.00(8.00-11.25) & 13.50(11.50-17.00) days] and LPV/r+IFN+Arbidol [14.00(9.75-19.00) & 19.50(13.25-24.00) days]. In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r+Novaferon or adding Arbidol based on LPV/r+IFN may not improve the efficacy.